Applied DNA Sciences Elects New Directors, Adjusts Executive Pay
Ticker: BNBX · Form: 8-K · Filed: Nov 10, 2025 · CIK: 744452
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: APDN
TL;DR
APDN adds 2 directors, rejigs CEO/CFO pay packages.
AI Summary
Applied DNA Sciences, Inc. announced on November 6, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Kenneth L. Miller and Mr. Robert L. B. Jr., to its board, effective November 6, 2025. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. James A. Hayward, and Chief Financial Officer, Ms. Melissa L. St. Clair, detailing their compensation and severance packages.
Why It Matters
The election of new directors and adjustments to executive compensation can signal strategic shifts or governance changes within the company, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal restructuring or strategic pivots, which carry inherent risks.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- November 6, 2025 (date) — Effective date of director elections and reporting date
- Dr. Kenneth L. Miller (person) — Newly elected director
- Mr. Robert L. B. Jr. (person) — Newly elected director
- Dr. James A. Hayward (person) — Chief Executive Officer
- Ms. Melissa L. St. Clair (person) — Chief Financial Officer
FAQ
Who were the new directors elected to the Applied DNA Sciences board?
Dr. Kenneth L. Miller and Mr. Robert L. B. Jr. were elected as new directors.
When were the new directors' appointments effective?
The appointments of the new directors were effective as of November 6, 2025.
What key executive positions had new employment agreements entered into?
New employment agreements were entered into with the Chief Executive Officer, Dr. James A. Hayward, and the Chief Financial Officer, Ms. Melissa L. St. Clair.
What is the company's state of incorporation?
Applied DNA Sciences, Inc. is incorporated in Delaware.
What is the company's primary business address?
The company's business address is 50 Health Sciences Drive, Stony Brook, NY 11790.
Filing Stats: 1,309 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2025-11-10 17:01:29
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value BNBX The Nasdaq Stock Mar
- $60,000 — ment, the Company pays a monthly fee of $60,000 to the Strategic Advisor and, in connec
- $250,002.64 — tock for an aggregate purchase price of $250,002.64. Also as previously disclosed, on Sept
Filing Documents
- tm2530716d1_8k.htm (8-K) — 28KB
- 0001104659-25-109267.txt ( ) — 189KB
- apdn-20251106.xsd (EX-101.SCH) — 3KB
- apdn-20251106_lab.xml (EX-101.LAB) — 33KB
- apdn-20251106_pre.xml (EX-101.PRE) — 22KB
- tm2530716d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 6, 2025, the Board of Directors (the "Board") of Applied DNA Sciences, Inc. (the "Company"), upon recommendation of the Nominating Committee of the Board, appointed Joshua Kruger to serve as its Chairman and as a director. At the time of Mr. Kruger's appointment, the Board had a vacancy as the result of the previously disclosed resignation on September 29, 2025 of Sanford R. Simon. Mr. Kruger replaced Judith Murrah as Chairman, who voluntarily resigned from her position as Chairperson of the Board effective November 6, 2025. Ms. Murrah will continue to serve as a director of the Company. Ms. Murrah's resignation as Chairperson is not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices. The Board has determined that Mr. Kruger does not satisfy the independence criteria set forth in the Nasdaq rules and is not "independent" for purposes of serving on the Board. For his services as Chairman, Mr. Kruger is expected to receive the same annual compensation as the Company's other non-employee directors, if any. In connection with Mr. Kruger's appointment to the Board, the Company will enter into its standard form of indemnification agreement for directors and officers (the "Indemnification Agreement") with Mr. Kruger. Pursuant to the terms of the Indemnification Agreement, the Company may be required, among other things, to indemnify Mr. Kruger for certain expenses, including reasonable attorneys' fees, retainers, court costs, transcripts, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses incurred by him in any action, proceeding or appeal arising out of his service on the Board
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. APPLIED DNA SCIENCES, INC. Dated: November 10, 2025 By: /s/ Clay Shorrock Name: Clay Shorrock Title: Chief Executive Officer